DEPO-PROVERA

BRAIN TUMOR LAWSUIT

What Is Depo-Provera?

Depo-Provera is a widely used contraceptive marketed under the brand names Depo-Provera and the lower-dose Depo-SubQ Provera 104. Depo-Provera is a hormonal birth control injection approved by the U.S. Food and Drug Administration (FDA) in 1992 and inhibits ovulation by thickening cervical mucus and thinning the uterine lining. It is typically into the arm or the buttocks every 12 weeks. Depo-Provera is highly effective and may also be prescribed for managing other conditions, such as:

Cancer treatment
Chronic pelvic pain
Contraception
Endometriosis
Hirsutism

Hormonal imbalances
Menstrual disorders
Postpartum bleeding
Reduce cancer risk
Reduce ovarian cysts
Uterine fibroids

In recent years, Depo-Provera has come under scrutiny after research linked the drug’s ingredients to an increased risk of meningioma brain tumors.

How Does Depo-Provera Cause Brain Tumors?

Medical research indicates that long-term use of medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera, causes more than five times the risk for brain tumors. MPA binds to progesterone receptors in the protective layers surrounding the brain and spinal cord, triggering abnormal cell growth that may contribute to the development of meningiomas.

With such increased risks and approximately 74 million users globally, Depo-Provera may be considered a potentially significant public health concern.

What Are the Symptoms of Meningioma Brain Tumors?

Symptoms of meningioma vary depending on the size and location of the tumor and include:

Blurred or double vision
Confusion or disorientation
Difficult speaking
Headaches, particularly in the morning
Hearing loss

Loss of balance or vertigo
Loss of smell
Memory loss
Seizures
Tinnitus (ringing in the ears)
Weakness or numbness in limbs

What Is a Depo-Provera Lawsuit?

Depo-Provera is linked to an increased risk of meningioma and other brain tumors. Early indications reveal that Pfizer knew or should have known about the risks but failed to warn healthcare professionals or consumers. Women who have received at least two Depo-Provera injections may qualify for compensation if they have been diagnosed with any of the following conditions:

Benign or malignant brain tumors
Meningioma
Pseudotumor cerebri

We are investigating claims for women who have been administered Depo-Provera injections and subsequently been diagnosed with brain tumors that could have been avoided with adequate warnings about the risk. As more information about the risks associated with Depo-Provera becomes available, we anticipate an increase in lawsuits against Pfizer in the coming years.